Limited work currently exists in the literature regarding the role of albumin supplementation in the context of operative spinal metastatic disease and concurrent systemic chemotherapeutic treatments, however our review may aid in providing a foundation to develop albumin monitoring and supplementation protocols in this largely frail patient population. The gene discussed is ALB; the disease is metastatic neoplasm.